All In Biotech

Drug Trial Radar · NCT00353496

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours

Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour

Last checked: Nov 20, 2026Latest source record: Mar 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 264 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

264

Actual

Start

Jun 2006

Primary completion

Apr 2013

Study completion Apr 2013

Sponsor

Lead sponsor
IpsenIndustry
Sponsor type
Industry
First posted
Jul 18, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will compare the difference between lanreotide Autogel and placebo on progression free survival in patients who have an endocrine tumour in the pancreas or intestines.

Conditions

  • Endocrine Tumors

Interventions

  • lanreotide (Autogel formulation)Drug

    120mg administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.

  • PlaceboDrug

    Saline solution 0.9% administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: From randomisation up to the last tumour assessment (scheduled at 96 weeks). Radiological scans were performed every 12 weeks during the first year and every 24 weeks during the second year

Locations

71 sites in 15 countries. Site status is shown where the registry gives one.

  • Cedars-Sinai Outpatient Cancer Center

    Los Angeles, California

  • University of Iowa

    Iowa City, Iowa

  • The John Hopkins Hospital

    Baltimore, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Providence Portland Medical Center

    Portland, Oregon

  • MD Anderson Cancer Center

    Houston, Texas

  • University of Wisconsin School of Medicine and Public Health

    Madison, Wisconsin

  • University Hospital

    Vienna, Austria

  • UZ Antwerpen

    Antwerp, Belgium

  • UCL Saint Luc

    Brussels, Belgium

  • UZ Gent

    Ghent, Belgium

  • Fekultni nemocnice Olomouc

    Olomouc, Czechia

  • General faculty

    Prague, Czechia

  • Fakultni nemocnice Na

    Bulovce, Prague, Czechia

  • Sygehus Hospital

    Aarhus, Denmark

  • Rigshospitalet

    Copenhagen, Denmark

  • Hôpital A. Paré

    Boulogne-Billancourt, France

  • Hôpital Beaujon

    Clichy, France

  • CAC Oscar Lambret

    Lille, France

  • Hôpital Edouard Herriot

    Lyon, France

  • CHU la Timone

    Marseille, France

  • Hôpital R. Debré

    Reims, France

  • CHI Frejus St Raphael

    Saint-Raphaël, France

  • Hôpital Rangueil

    Toulouse, France

  • Unité de gastro enterologie IGR

    Villejuif, France

  • Charite Hospital

    Berlin, Germany

  • University Hospital

    Erlangen, Germany

  • University Hospital

    Lübeck, Germany

  • Gutenberg University Hospital

    Mainz, Germany

  • University Hospital

    München, Germany

  • Lukas Hospital

    Neuss, Germany

  • Global Hospital

    Hyderabad, India

  • Tata Memorial Hospital

    Mumbai, India

  • Centro di Refierimiento Oncologica

    Aviano, Italy

  • Azienda Malpighi

    Bologna, Italy

  • INSCT

    Milan, Italy

  • University of Naples

    Naples, Italy

  • Hospital S. Chiara

    Pisa, Italy

  • Azienda San Giovanni Battista

    Torino, Italy

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.